CN100441194C - Breviscapine dry suspension - Google Patents
Breviscapine dry suspension Download PDFInfo
- Publication number
- CN100441194C CN100441194C CNB2004100166840A CN200410016684A CN100441194C CN 100441194 C CN100441194 C CN 100441194C CN B2004100166840 A CNB2004100166840 A CN B2004100166840A CN 200410016684 A CN200410016684 A CN 200410016684A CN 100441194 C CN100441194 C CN 100441194C
- Authority
- CN
- China
- Prior art keywords
- breviscapine
- dry suspension
- scutellarin
- magnesium stearate
- auxiliary materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明属药物制剂领域，涉及一种用于治疗心脑血管疾病的含灯盏花素的干混悬剂药物制剂。本发明以灯盏花素为活性成分，添加适宜辅料如填充剂、助悬剂、助流剂、润滑剂和矫味剂，通过干燥粉碎后，用等量递加法将活性成分与辅料混均，制成干混悬剂。本发明干混悬剂固体粉末的流动性好，加水搅拌后可迅速转变为均匀、稳定的混悬剂，沉降速率慢，再分散性良好，便于患者服用。经动物实验证实，本制剂起效快、生物利用度高，是普通片的10倍以上，并且制备方法简单、使用方便。The invention belongs to the field of pharmaceutical preparations, and relates to a dry suspension pharmaceutical preparation containing scutellarin for treating cardiovascular and cerebrovascular diseases. In the present invention, scutellarin is used as an active ingredient, and appropriate auxiliary materials such as fillers, suspending agents, glidants, lubricants and flavoring agents are added, and after being dried and pulverized, the active ingredient and auxiliary materials are mixed uniformly by an equal-amount incremental method, Prepare a dry suspension. The dry suspension solid powder of the present invention has good fluidity, can be rapidly transformed into a uniform and stable suspension after being stirred with water, has slow sedimentation rate, good redispersibility, and is convenient for patients to take. It is confirmed by animal experiments that the preparation has quick action and high bioavailability, which is more than 10 times that of ordinary tablets, and the preparation method is simple and convenient to use.
Description
技术领域 technical field
本发明属药物制剂领域，涉及一种用于治疗心脑血管疾病的药物制剂。具体涉及一种含灯盏花素的干混悬剂。The invention belongs to the field of pharmaceutical preparations and relates to a pharmaceutical preparation for treating cardiovascular and cerebrovascular diseases. Specifically relates to a dry suspension containing breviscapine.
背景技术 Background technique
灯盏花素(Brevescapine)是从菊科植物短葶飞蓬(原名灯盏花，又名灯盏细辛，Erigeron Breviscapus(Vant.)Hand.-Mazz.)中分离得到的一类黄酮类物质，主要含灯盏乙素(Scutellarin，化学名为4’，5，6-三羟基黄酮-7-葡萄糖醛酸苷)，还含有少量灯盏甲素及其他黄酮类成分。Brevescapus (Brevescapine) is a class of flavonoids isolated from the Compositae plant Brevescapus (formerly known as Breviscapus, also known as Erigeron Breviscapus (Vant.) Hand.-Mazz.), mainly containing Brevescapus Scutellarin (chemically named 4',5,6-trihydroxyflavone-7-glucuronide) also contains a small amount of scutellarin and other flavonoids.
已有的药效学研究表明，灯盏花素具有扩张脑血管，降低脑血管阻力，增加脑血流量，改善微循环，提高血脑屏障通透性，增强机体巨噬细胞吞噬免疫作用，对抗垂体后叶素所致脑缺血、缺氧，并能对抗由二磷酸腺苷(ADP引起的血小板凝胶作用。灯盏花素在临床上广泛用于治疗脑血栓、脑梗塞以及类型未定的中风后瘫痪等症，对心、肝、脾、肺、肾和胃功能无损害，也未见明显的毒副作用。Existing pharmacodynamic studies have shown that breviscapine can dilate cerebral blood vessels, reduce cerebral vascular resistance, increase cerebral blood flow, improve microcirculation, improve blood-brain barrier permeability, enhance the phagocytic immune function of macrophages in the body, and resist the pituitary gland. Cerebral ischemia and hypoxia caused by vasopressin, and can resist the platelet gel effect caused by adenosine diphosphate (ADP). Breviscapine is widely used clinically in the treatment of cerebral thrombosis, cerebral infarction and undetermined types of post-stroke Paralysis and other diseases have no damage to heart, liver, spleen, lung, kidney and stomach functions, and no obvious toxic and side effects have been seen.
目前以灯盏花素为原料的上市制剂品种有灯盏花素注射液、灯盏细辛注射液、灯盏花素片、灯盏花颗粒和益脉康片，所述上市品种均已有国家标准。除此之外，目前处于新药申报阶段，或申请专利阶段的制剂还有灯盏花素分散片、滴丸、缓释片、控释片、软胶囊和输液等。Currently, there are breviscapine-based preparations on the market including breviscapine injection, breviscapine injection, breviscapine tablets, breviscapine granules and Yimaikang tablets, all of which have national standards. In addition, preparations that are currently in the new drug declaration stage or patent application stage include breviscapine dispersible tablets, dropping pills, sustained-release tablets, controlled-release tablets, soft capsules, and infusion solutions.
由于灯盏花素为黄酮类成分，其水溶性和脂溶性均很差，因此口服的普通颗粒剂和片剂常因溶出度问题导致药物起效缓慢，生物利用度差；目前虽然有分散片、滴丸等口服速释制剂，但均未报道其体内药动学特征和生物利用度。灯盏花素注射给药虽然吸收快，生物利用度高，但使用不方便，患者顺应性差，且制备、包装、运输、贮存均不方便。因此开发速效、高生物利用度，且使用方便的灯盏花素制剂是十分必要的。Because breviscapine is a flavonoid component, its water solubility and fat solubility are very poor, so the common granules and tablets taken orally often have slow onset of action and poor bioavailability due to dissolution problems; although there are currently dispersible tablets, Oral immediate-release preparations such as dropping pills, but their pharmacokinetic characteristics and bioavailability in vivo have not been reported. Although breviscapine injection has fast absorption and high bioavailability, it is inconvenient to use, poor patient compliance, and inconvenient to prepare, pack, transport and store. Therefore, it is necessary to develop a quick-acting, high bioavailability, and easy-to-use scutellarin preparation.
发明内容 Contents of the invention
本发明的目的是提供一种起效快、生物利用度高、制备简单、服用方便的灯盏花素药物新剂型——灯盏花素干混悬剂。The purpose of the present invention is to provide a new dosage form of breviscapine drug—breviscapine dry suspension with quick onset, high bioavailability, simple preparation and convenient administration.
本发明所述的灯盏花素干混悬剂以灯盏花素(市售)为活性成分，并添加适宜辅料制成干混悬剂。The breviscapine dry suspension of the present invention uses breviscapine (commercially available) as an active ingredient, and adds appropriate auxiliary materials to make a dry suspension.
本发明所述的灯盏花素干混悬剂中灯盏花素的含量为单剂量包装中含灯盏花素5～500mg。The content of breviscapine in the breviscapine dry suspension of the present invention is 5-500 mg of breviscapine in a single-dose package.
本发明所述的灯盏花素干混悬剂中的辅料包括但不限于填充剂、助悬剂、助流剂、润滑剂、表面活性剂和矫味剂。The auxiliary materials in the scutellarin dry suspension of the present invention include but not limited to fillers, suspending agents, glidants, lubricants, surfactants and flavoring agents.
本发明所述的填充剂包括但不限于淀粉、预胶化淀粉、糊精、乳糖、蔗糖、甘露醇、微晶纤维素、葡萄糖、木糖醇、山梨醇、硫酸钙、葡萄糖酸钙、磷酸钙、磷酸氢钙、碳酸钙和碳酸氢钙。The fillers described in the present invention include but are not limited to starch, pregelatinized starch, dextrin, lactose, sucrose, mannitol, microcrystalline cellulose, glucose, xylitol, sorbitol, calcium sulfate, calcium gluconate, phosphoric acid Calcium, calcium hydrogen phosphate, calcium carbonate and calcium bicarbonate.
所述的助悬剂包括但不限于阿拉伯胶、西黄蓍胶、桃胶、白及胶、果胶、明胶、瓜耳树胶、角叉菜胶、淀粉、海藻酸钠、脱乙酰甲壳素、甲基纤维素、羧甲基纤维素钠、羟丙基纤维素、羟丙甲基纤维素、羟乙基纤维素、卡波姆、微晶纤维素、聚维酮、葡聚糖、聚丙烯酸钠和硅藻土。The suspending agent includes but not limited to gum arabic, tragacanth gum, peach gum, white gelatin, pectin, gelatin, guar gum, carrageenan, starch, sodium alginate, chitosan, Methylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, carbomer, microcrystalline cellulose, povidone, dextran, polyacrylic acid Sodium and diatomaceous earth.
所述的助流剂包括但不限于微粉硅胶和滑石粉。The glidant includes but not limited to micronized silica gel and talcum powder.
所述的润滑剂包括但不限于硬脂酸、硬脂酸镁、硬脂酸钙、硬脂酸锌、滑石粉、氢化植物油、单硬脂酸甘油酯、聚乙二醇4000、聚乙二醇6000、聚乙二醇8000、月桂醇硫酸钠和月桂醇硫酸镁。The lubricant includes but not limited to stearic acid, magnesium stearate, calcium stearate, zinc stearate, talc, hydrogenated vegetable oil, glyceryl monostearate, polyethylene glycol 4000, polyethylene glycol Alcohol 6000, Macrogol 8000, Sodium Lauryl Sulfate, and Magnesium Lauryl Sulfate.
所述的表面活性剂包括但不限于司盘、吐温、卖泽、苄泽、泊洛沙姆、蔗糖脂肪酸酯、十二烷基硫酸钠和磷脂。Said surfactants include, but are not limited to, Span, Tween, Maize, Benzazol, Poloxamer, sucrose fatty acid esters, sodium lauryl sulfate and phospholipids.
所述的矫味剂包括但不限于甜菊素、果糖、葡萄糖、果葡糖浆、蜂蜜、阿斯巴坦、蛋白糖、木糖醇、甘露醇、乳糖、山梨醇、麦芽糖醇、甘草甜素、干茶叶素、环已氨基磺酸钠、香蕉糖精、菠萝糖精、橘子糖精、薄荷糖精、茴香、香兰素、柠檬香精、樱桃香精和玫瑰香精。The flavoring agent includes but not limited to stevia, fructose, glucose, fructose syrup, honey, aspartame, protein sugar, xylitol, mannitol, lactose, sorbitol, maltitol, glycyrrhizin, Dried tea leaves, sodium cyclamate, banana sweetener, pineapple sweetener, orange sweetener, mint sweetener, anise, vanillin, lemon flavor, cherry flavor and rose flavor.
本发明灯盏花素干混悬剂通过下述方法制备，Breviscapine dry suspension of the present invention is prepared by the following method,
取灯盏花素粉碎后过120目筛，除矫味剂外的其它辅料分别干燥粉碎过100目筛。用等量递加法将活性成分与填充剂、助悬剂混合均匀，再加入助流剂、润滑剂、矫味剂充分混合均匀成固体粉末，分装即得。The breviscapine was crushed and passed through a 120-mesh sieve, and other auxiliary materials except the flavoring agent were dried and crushed through a 100-mesh sieve. Mix the active ingredients with fillers and suspending agents uniformly by equal amount addition method, then add glidants, lubricants and flavoring agents, mix them well to form solid powder, and pack them separately to get the product.
本发明所述的灯盏花素干混悬剂固体粉末的流动性良好，加水搅拌后可迅速转变为均匀、稳定的混悬剂，沉降速率慢，再分散性良好，便于患者服用。The breviscapine dry suspension solid powder of the present invention has good fluidity, can be rapidly transformed into a uniform and stable suspension after being stirred with water, has slow sedimentation rate, good redispersibility, and is convenient for patients to take.
对本发明所述的灯盏花素干混悬剂进行了兔体内的绝对生物利用度研究。结果表明，兔口服本发明120mg(以灯盏花素计)后，药物吸收迅速，达峰时间短(Tmax≈0.25～0.5h)、血药浓度高(Cmax≈10～30μg/ml)，与静脉注射比较，干混悬剂的绝对生物利用度约为20％～45％，是普通片的10倍以上。Absolute bioavailability research in rabbits was carried out on the dry suspension of breviscapine described in the present invention. The results show that after oral administration of 120 mg of the present invention (calculated as breviscapine) to rabbits, the drug is absorbed rapidly, the peak time is short (T max ≈0.25～0.5h), and the blood drug concentration is high (C max ≈10～30 μg/ml). Compared with intravenous injection, the absolute bioavailability of dry suspension is about 20% to 45%, which is more than 10 times that of ordinary tablets.
结果证实，本发明制剂具有见效快、生物利用度高、药效强的优点。并且制备方法简单、使用方便。The results prove that the preparation of the invention has the advantages of quick effect, high bioavailability and strong drug efficacy. Moreover, the preparation method is simple and the use is convenient.
附图说明 Description of drawings
图1是兔口服干混悬剂后的血浓曲线。Figure 1 is the blood concentration curve of rabbits after oral administration of dry suspension.
具体实施方式： Detailed ways:
下面以本发明的实施例为基础详细说明本发明，但本发明并不局限于此。The present invention will be described in detail below based on the embodiments of the present invention, but the present invention is not limited thereto.
实施例1Example 1
灯盏花素 20gBreviscapine 20g
微晶纤维素 200gMicrocrystalline Cellulose 200g
聚维酮 20gPovidone 20g
微粉硅胶 10gMicropowder silica gel 10g
硬脂酸镁 10gMagnesium stearate 10g
矫味剂 10gFlavoring agent 10g
乳糖 加至1000gAdd lactose to 1000g
按上述组分量，取灯盏花素粉碎后过120目筛，除矫味剂外的其它辅料分别干燥粉碎过100目筛，用等量递加法将活性成分灯盏花素与微晶纤维素、聚维酮、乳糖混合均匀，再加入微粉硅胶、硬脂酸镁和矫味剂充分混合均匀成固体粉末，按单剂量分装。共制1000袋，每袋重1g，其中含灯盏花素20mg。According to the amount of the above components, breviscapine was crushed and passed through a 120-mesh sieve, and other auxiliary materials except the flavoring agent were dried and crushed through a 100-mesh sieve, and the active ingredient scutellarin, microcrystalline cellulose, poly Mix vitamin ketone and lactose evenly, then add micropowder silica gel, magnesium stearate and flavoring agent, mix thoroughly and evenly to form a solid powder, and pack in single doses. A total of 1000 bags were made, each weighing 1g, containing 20mg of scutellarin.
实施例2Example 2
灯盏花素 20gBreviscapine 20g
微晶纤维素 50gMicrocrystalline Cellulose 50g
羟乙基纤维素 100gHydroxyethyl Cellulose 100g
微粉硅胶 10gMicropowder silica gel 10g
硬脂酸镁 10gMagnesium stearate 10g
甘露醇 加至1000gAdd mannitol to 1000g
按上述组分量，取灯盏花素粉碎后过120目筛，其它辅料分别干燥粉碎过100目筛。用等量递加法将活性成分灯盏花素与微晶纤维素、羟乙基纤维素、甘露醇混合均匀，再加入微粉硅胶、硬脂酸镁充分混合均匀，按单剂量分装。共制1000袋，每袋1g，含灯盏花素20mg。According to the amount of the above components, the breviscapine was crushed and passed through a 120-mesh sieve, and other auxiliary materials were dried and crushed through a 100-mesh sieve. The active ingredient breviscapine is uniformly mixed with microcrystalline cellulose, hydroxyethyl cellulose, and mannitol by an equal-volume incremental method, and then micro-powdered silica gel and magnesium stearate are added, fully mixed, and packaged in a single dose. A total of 1000 bags were made, each bag 1g, containing 20mg scutellarin.
实施例3Example 3
灯盏花素 40gBreviscapine 40g
羟丙甲基纤维素 100gHypromellose 100g
羧甲基纤维素钠 40gSodium carboxymethyl cellulose 40g
微粉化滑石粉 10gMicronized talc powder 10g
硬脂酸镁 10gMagnesium stearate 10g
矫味剂 10gFlavoring agent 10g
甘露醇 加至1000gAdd mannitol to 1000g
按上述组分量，取灯盏花素粉碎后过120目筛，除矫味剂外的其它辅料分别干燥粉碎过100目筛。用等量递加法将活性成分灯盏花素与羟丙甲基纤维素、羧甲基纤维素钠、甘露醇混合均匀，再加入微粉化滑石粉、硬脂酸镁和矫味剂充分混合均匀，按单剂量分装。共制1000袋，每袋1g，含灯盏花素40mg。According to the amount of the above components, the breviscapine was crushed and passed through a 120-mesh sieve, and other auxiliary materials except the flavoring agent were dried and crushed through a 100-mesh sieve. The active ingredient scutellarin, hydroxypropylmethylcellulose, sodium carboxymethylcellulose and mannitol were mixed uniformly by the method of equal incremental addition, and then micronized talcum powder, magnesium stearate and flavoring agent were added to fully mix uniformly, Packed in single doses. A total of 1000 bags were made, each bag 1g, containing breviscapine 40mg.
实施例4：Example 4:
灯盏花素 40gBreviscapine 40g
羟乙基纤维素 200gHydroxyethyl Cellulose 200g
微粉硅胶 50gMicropowder silica gel 50g
硬脂酸镁 10gMagnesium stearate 10g
矫味剂 10gFlavoring agent 10g
糖粉 加至1000gAdd powdered sugar to 1000g
按上述组分量，取灯盏花素粉碎后过120目筛，除矫味剂外的其它辅料分别干燥粉碎过100目筛。用等量递加法将活性成分灯盏花素与羟乙基纤维素、糖粉混合均匀，再加入微粉硅胶、硬脂酸镁和矫味剂充分混合均匀，按单剂量分装。共制1000袋，每袋1g，含灯盏花素40mg。According to the amount of the above components, the breviscapine was crushed and passed through a 120-mesh sieve, and other auxiliary materials except the flavoring agent were dried and crushed through a 100-mesh sieve. The active ingredient breviscapine is uniformly mixed with hydroxyethyl cellulose and powdered sugar by an equal-volume incremental method, then micronized silica gel, magnesium stearate and flavoring agents are added, fully mixed and uniformly distributed, and packaged in single doses. A total of 1000 bags were made, each bag 1g, containing breviscapine 40mg.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100166840A CN100441194C (en) | 2004-03-03 | 2004-03-03 | Breviscapine dry suspension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100166840A CN100441194C (en) | 2004-03-03 | 2004-03-03 | Breviscapine dry suspension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1559424A CN1559424A (en) | 2005-01-05 |
| CN100441194C true CN100441194C (en) | 2008-12-10 |
Family
ID=34440581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100166840A Expired - Fee Related CN100441194C (en) | 2004-03-03 | 2004-03-03 | Breviscapine dry suspension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100441194C (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100425242C (en) * | 2005-09-26 | 2008-10-15 | 云南昊邦制药有限公司 | Erigeron breviscapus effervescent dry mixed suspension and its making method |
| CN101185653B (en) * | 2006-10-16 | 2012-09-05 | 复旦大学 | Breviscapine oral administration composition and preparation method thereof |
| CN101637441B (en) * | 2008-07-28 | 2011-11-23 | 广州达信生物技术有限公司 | Moguisteine dried suspension and preparation method thereof |
| CN102232929A (en) * | 2010-05-06 | 2011-11-09 | 杭州赛利药物研究所有限公司 | Voriconazole dried suspension and preparation method thereof |
| CN103006556B (en) * | 2012-10-31 | 2014-11-26 | 澳门科技大学 | Scutellarin nanosuspension and preparation method thereof |
| CN107929243A (en) * | 2017-12-11 | 2018-04-20 | 河南惠通天下生物工程有限公司 | A kind of thiabendazolum dry suspensoid agent and preparation method thereof |
| CN118078747A (en) * | 2022-11-27 | 2024-05-28 | 江苏神猴医药研究有限公司 | A kind of crude drug powder dry suspension and its preparation process |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1341420A (en) * | 2001-09-11 | 2002-03-27 | 上海绿谷伟业生态工程有限公司 | Medicine formed from ganglioside and erigeron breviscapus extract and health-care product and their application |
| CN1437950A (en) * | 2002-12-21 | 2003-08-27 | 李睿宇 | Herba florigen oral drip-ball and production method |
| CN1457782A (en) * | 2003-05-17 | 2003-11-26 | 南昌弘益科技有限公司 | Dry spaxxacin suspension agent for resisting bacterial infection and its preparing method |
-
2004
- 2004-03-03 CN CNB2004100166840A patent/CN100441194C/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1341420A (en) * | 2001-09-11 | 2002-03-27 | 上海绿谷伟业生态工程有限公司 | Medicine formed from ganglioside and erigeron breviscapus extract and health-care product and their application |
| CN1437950A (en) * | 2002-12-21 | 2003-08-27 | 李睿宇 | Herba florigen oral drip-ball and production method |
| CN1457782A (en) * | 2003-05-17 | 2003-11-26 | 南昌弘益科技有限公司 | Dry spaxxacin suspension agent for resisting bacterial infection and its preparing method |
Non-Patent Citations (2)
| Title |
|---|
| 高效液相色谱法测定灯盏花素分散片中灯盏乙素的含量. 邹薇，何国华，魏东峰.中药新药与临床药理，第14卷第3期. 2003 |
| 高效液相色谱法测定灯盏花素分散片中灯盏乙素的含量. 邹薇，何国华，魏东峰.中药新药与临床药理，第14卷第3期. 2003 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1559424A (en) | 2005-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2951457T3 (en) | Pharmaceutical compositions comprising iron oxy-hydroxide | |
| CN101352449B (en) | Vitamin orally disintegrating tablet and preparation method thereof | |
| KR960011772B1 (en) | Oral dosing formulations of dideoxy purine nucleosides | |
| CA1339463C (en) | Effervescent tablet containing a salicylic acid-forming agent | |
| JP5944615B2 (en) | Solid preparation for internal use | |
| KR101203186B1 (en) | Taste-masked pharmaceutical composition for oral administration and a process for the preparation thereof | |
| CN104587260B (en) | The composition of bamboo-leaves flavones and chitosan oligosaccharide, its preparation method and application | |
| US12303514B2 (en) | Immediate and controlled release appetite suppressant compositions for weight loss | |
| CN104922145A (en) | Composition of gamma-aminobutyric acid and chitosan oligosaccharide, as well as preparation method and applications of composition | |
| HU224983B1 (en) | Swallow tablet comprising paracetamol | |
| WO2008122190A1 (en) | The composition comprising l-carnitine or derivatives thereof and its use | |
| CN101129351A (en) | A kind of iron supplement composition, its preparation method and application | |
| CN100441194C (en) | Breviscapine dry suspension | |
| CN104825873A (en) | Composition of EGCG and bamboo leaf flavonoid, preparation method and applications thereof | |
| US20070264370A1 (en) | Composition and methods for the treatment of joint pain using Angelica gigas Nakai extract and powder as combined with Glucosamine Sulfate, or Chondroitin Sulfate and HCL, or MSM, or aspirin, or Celedrin, and as combinations thereof in powder, pill, capsule, spray, liquid, and gelcap form | |
| US6509035B1 (en) | Oral preparation of coenzyme a useful for lowering blood lipid and a method producing for same | |
| CN104840800B (en) | Bamboo-leaves flavones and the composition of γ-aminobutyric acid and its preparation method and application | |
| CN104739816B (en) | Bad Portugal's zinc medical composition and its use including chiral photo-isomerisation compound | |
| CN101897709A (en) | Drug composition containing small dosage of folic acid and aspirin and application thereof | |
| KR101210831B1 (en) | Colonic purgative composition comprising polyethylene glycol and vitamin c | |
| CN104825441A (en) | EGCG and gamma-aminobutyric acid composition, and preparation method and applications thereof | |
| CN104645334B (en) | N acetylcysteine activated carbon composites and its preparation method and application | |
| CZ79593A3 (en) | Antitussive preparation | |
| CN102552398A (en) | Medicinal composition of radix salviae miltiorrhizae extract and application thereof | |
| CN104739776A (en) | Solid dispersion composition of levocarnitine as well as preparation method and medical application of solid dispersion composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081210 Termination date: 20110303 |